About US
Contact us
-
Fierce Pharma Asia—Pfizer's China biosim retreat; WuXi Bio's buying spree; Fujifilm's $2B plantPfizer is retreatingfromChina's biosimilar market, ending development of three programs and selling a biologics plant pegged to make them to WuXi Biologics. In addition to the Pfizer deal, the Chines2021/3/23
-
Incyte, Novartis aim to make Jakafi available in severe COVID-19 after narrow trial missOver the span of more than a year during the pandemic, pharma companies of all stripes have tested their existing medicines against COVID-19. Incyte is one of them. Unfortunately, Incyte’s Jakafi fel2021/3/23
-
Challenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for TremfyaWhen Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bol2021/3/18
-
In wake of biopharma mega buyouts, FTC kicks off review of industry's dealmakingBristol Myers Squibb and Celgene. AbbVie and Allergan. Pfizer's Upjohn unit and generics giant Mylan. These arethree of the biggest pharma mergers of the past couple years. They're also the kind of d2021/3/18
-
Specialty drugmaker ANI to boost CDMO work, generics portfolio with $210M Novitium buyoutSpecialty drugmaker ANI Pharmaceuticals has been steadily growing its generics arsenal over the past decade while also striving to expand itsCDMO business. Now, the company has inkeda deal to fuel bo2021/3/16
-
Pfizer's COVID-19 vaccine faced EMA manufacturing concerns ahead of emergency nod: reportAbout a month before Pfizer and BioNTech won an emergency nod for theirCOVID-19 vaccine in Europe, regulators raised flags about lower-than-expected levelsof intact mRNAin commercial batches, the BMJ2021/3/16
-
Johnson & Johnson runs into vaccine supply issues in Europe, threatening second-quarter delivery pledge: ReutersJohnson & Johnson execs have assured investors and officials that the company is "comfortable" hitting its vaccine delivery targets. But with its U.S. rollout underway,the pharma gianthas run int2021/3/10
-
Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?First it was heart disease, now it’s non-small cell lung cancer (NSCLC). Novartis can’t seem to make its canakinumab injection work outside immunology, where the drug’s currently sold as Ilaris. The2021/3/10
-
Roche is gearing up to knock down an Irish plant—and it's complicatedUnable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed f2021/3/8
-
U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warnsThe U.S.' move to lock up raw materials and supplies forPfizer's COVID-19 vaccine could spell trouble for manufacturers working on other shots around the globe. The world’s largest vaccine maker by v2021/3/8